ophthalmologyОфтальмологияOphthalmology in Russia1816-50952500-0845Ophthalmology10.18008/1816-5095-2021-4-784-790ophthalmology-1680Research ArticleОБЗОРЫREVIEWSПрименение бромфенака в офтальмологической практике (обзор литературы)The Use of Bromfenac Ophthalmic Solution in Clinical Practice (Literature Review)МатюхинаЕ. Н.MatyukhinaE. N.

Матюхина Екатерина Николаевна, врач-офтальмолог

ул. Пушкина, 90, Уфа, 450008

Matyukhina Ekaterina N., ophthalmologist

Pushkin str., 90, Ufa, 450008

ok5882@yandex.ruГБУ «Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан»РоссияUfa Eye Research Institute the Academy of Sciences of the Republic of BashkortostanRussian Federation202128122021184784790Copyright © Матюхина Е.Н., 20212021Матюхина Е.Н.Matyukhina E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ophthalmojournal.com/opht/article/view/1680

В настоящее время огромную роль в лечении воспалительных заболеваний глаз играют нестероидные противовоспалительные препараты. При лечении любого воспалительного процесса перед офтальмологом встает вопрос выбора между глюкокортикоидными препаратами (ГКС) и нестероидными противовоспалительными препаратами (НПВС). При этом данные группы могут быть использованы как в комбинациях, так и в режиме монотерапии. Глюкокортикоиды широко и эффективно применяются в офтальмологии, но следует помнить о ряде серьезных побочных эффектов данной группы препаратов. При их применении возможно повышение офтальмотонуса, снижение иммунного ответа и репаративных процессов, также ГКС оказывают катарактогенное и ульцерогенное действие, в связи с этим необходимо их осторожное применение. НПВС по противовоспалительной активности уступают глюкокортикоидам. Их механизм действия связан с блокированием циклооксигеназы, угнетением синтеза простагландинов из арахидоновой кислоты. В связи с этим НПВС являются более предпочтительной группой при лечении воспалительных заболеваний глаз. Применение НПВС дает хороший анальгезирующий эффект, этот класс препаратов эффективен для профилактики макулярного отека различной этиологии и снижения риска развития воспаления в послеоперационном периоде. Одним из наиболее эффективных и наиболее современным НПВС для местного применения является производное фенилуксусной кислоты — бромфенак, который в своей формуле имеет атом брома, что повышает его липофильность, проникающую способность в ткани глаза, а также анальгезирующую и противовоспалительную активность. Бромфенак эффективен для купирования боли и всех признаков воспаления, вызванных заболеванием или хирургическим вмешательством, подавления развития макулярного отека различной этиологии, обладает антимиотическим эффектом. Также данная группа может быть использована после рефракционной хирургии для уменьшения боли и фотофобии, для облегчения зуда при аллергическом конъюнктивите. Двукратное применение данного препарата в течение суток, отсутствие ощущений дискомфорта и минимальное проявление побочных эффектов способствует повышению комплаентности пациента.

To this date nonsteroidal anti-inflammatory drugs play a huge role in the treatment of inflammatory eye diseases. Ophthalmologists face the question of choosing between glucocorticoid drugs (GCS) and nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of any inflammatory process. At the same time, these groups can be used both in combinations and in monotherapy mode. Glucocorticoids are widely and effectively used in ophthalmology, but it should be remembered about a number of serious side effects of this group of drugs. When using these drugs, it is possible to increase ophthalmotonus, decrease the immune response and reparative processes, also GCS have cataractogenic and ulcerogenic effects, and therefore it careful use is necessary. NSAIDs are inferior to glucocorticoids in anti-inflammatory activity. Its mechanism of action is associated with blocking cyclooxygenase, inhibition of prostaglandin synthesis from arachidonic acid. In this regard, NSAIDs are the preferred group in the treatment of inflammatory eye diseases. The use of NSAIDs gives a good analgesic effect, this class of drugs is effective for the prevention of macular edema of various etiologies and reducing the risk of inflammation in the postoperative period. One of the most effective and most modern NSAIDs for topical use is a derivative of phenylacetic acid — Bromophenac, which in its formula has a bromine atom, which increases its lipophilicity, penetrating ability into the tissues of the eye, as well as analgesic and anti-inflammatory activity. Bromfenac is effective for relieving pain and all signs of inflammation caused by disease or surgery, suppressing the development of macular edema of various etiologies, has an antimiotic effect. Also, this group can be used after refractive surgery to reduce pain and photophobia, to relieve itching in allergic conjunctivitis. Double use of this drug during the day, the absence of discomfort and minimal side effects contribute to improving the patient’s compliance.

бромфенакнестероидные противовоспалительные средствавоспалениеотек макулыbromfenacnonsteroidal anti-inflammatory drugsinflammationmacular edemaReferencesAnterior Segment Intraocular Inflammation (ASII): Guidelines. Eds BenEzra D., Ohno S, Secchi AG, Ali JL. 2000. 216 p. DOI: 10.1136/bjo.85.4.504aAnterior Segment Intraocular Inflammation (ASII): Guidelines. Eds BenEzra D., Ohno S, Secchi AG, Ali JL. 2000. 216 p. DOI: 10.1136/bjo.85.4.504aFitz Gerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. 2001;345(6):433–442. DOI: 10.1056/NEJM200108093450607Fitz Gerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. 2001;345(6):433–442. DOI: 10.1056/NEJM200108093450607McGhee C.N., Dean S., Danesh-Meyer H. Locally administered ocular corticoste roids: benefits and risks, Drug Saf, 2002;25:33–55.McGhee C.N., Dean S., Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks, Drug Saf, 2002;25:33–55.Flach A.J. Topicalnonsteroidal anti-inflammatory drugs in ophthalmology, Int Ophthalmol Clin, 2002;42:1–11.Flach A.J. Topicalnonsteroidal anti-inflammatory drugs in ophthalmology, Int Ophthalmol Clin, 2002;42:1–11.El-Harazi S.M., Ruiz R.S., Feldman R.M. A randomized double-masked trial com paring ketorolac tromethamine 0.5 %, diclofenac sodium 0.1 % and prednisolone acetate 1 % in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers. 1998;29:539–544.El-Harazi S.M., Ruiz R.S., Feldman R.M. A randomized double-masked trial comparing ketorolac tromethamine 0.5 %, diclofenac sodium 0.1 % and prednisolone acetate 1 % in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers. 1998;29:539–544.Roberts C.W., Brennan K.M. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol. 1995;113:725–727.Roberts C.W., Brennan K.M. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol. 1995;113:725–727.Asano S., Miyake K., Ota I. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized com parison of topical diclofenac 0.1 % and betamethasone 0.1 %. J Cataract Refract Surg. 2008;34:57–63.Asano S., Miyake K., Ota I. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1 % and betamethasone 0.1 %. J Cataract Refract Surg. 2008;34:57–63.Wolf E.J., Braunstein A., Shih C. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepaf enac. J Cataract Refract Surg. 2007;33:1546–1549.Wolf E.J., Braunstein A., Shih C. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33:1546–1549.Kessel L., Tendal B., Jorgensen K.J. Post-cataract prevention of inflammation and macular edema by steroid and NSAID: a systematic review. Ophthalmology. 2014;121(10):1915–1924.Kessel L., Tendal B., Jorgensen K.J. Post-cataract prevention of inflammation and macular edema by steroid and NSAID: a systematic review. Ophthalmology. 2014;121(10):1915–1924.Кукес В.Г. Клиническая фармакология М.: ГЭОТАР-Медицина, 1999. 528 с.Kukes V.G. Clinical pharmacology Moscow: GEOTAR-Medicina, 1999. 528 p. (In Russ.).Peneva P.T. Non-steroidal anti-inflammatory drugs for topical ophthalmic admin istration: contemporary trends. Int. J. Pharm. Pharm. Sci. 2015;7(9):13–19.Peneva P.T. Non-steroidal anti-inflammatory drugs for topical ophthalmic administration: contemporary trends. Int. J. Pharm. Pharm. Sci. 2015;7(9):13–19.Дугина А. Е. Победить воспаление: рациональное применение НПВС в оф тальмологии. Российский медицинский журнал. Клиническая офтальмология. 2015;3:139–145.Dugina A.E. Inflammation and rational usage of NSAIDS in ophthalmology. Russian Medical Journal. Clinical Ophthalmology = Rossijskiy medicinskiy zhurnal. Klinicheskaya oftal’mologiya. 2015;3:139–145 (In Russ.).Bucci F.A., Waterbury L.D., Amico L.M. Prostaglandin E 2 inhibition and aqueous concentration of ketorolac 0.4 % (Acular LS) and nepafenac 0.1 % (Nevanac) in pa tients undergoing phacoemulsification. Am. J. Ophthalmol. 2007;144(1):146–147. DOI: 10.1016/j.ajo.2007.02.034Bucci F.A., Waterbury L.D., Amico L.M. Prostaglandin E 2 inhibition and aqueous concentration of ketorolac 0.4 % (Acular LS) and nepafenac 0.1 % (Nevanac) in patients undergoing phacoemulsification. Am. J. Ophthalmol. 2007;144(1):146–147. DOI: 10.1016/j.ajo.2007.02.034Hoffman R.S., Braga-Mele R., Donaldson K. Emerick G., Henderson B., Kahook M., Mamalis N., Miller K., Realini T., Shorstein N., Stiverson R., Wirostkoet B. Cata ract surgery and nonsteroidal antiinflammatory drugs. J. Cataract Refract. Surg. 2016;42(9):1368–1379. DOI: 10.1016/j.jcrs.2016.06.006Hoffman R.S., Braga-Mele R., Donaldson K. Emerick G., Henderson B., Kahook M., Mamalis N., Miller K., Realini T., Shorstein N., Stiverson R., Wirostkoet B. Cataract surgery and nonsteroidal antiinflammatory drugs. J. Cataract Refract. Surg. 2016;42(9):1368–1379. DOI: 10.1016/j.jcrs.2016.06.006Kim, S.J., Flach A.J., Jampol L.M. Nonsteroidal anti-inflammatory drugs in oph thalmology. Surv. Ophthalmol. 2010;55(2):108–133. DOI: 10.1016/j.survoph thal.2009.07.005Kim, S.J., Flach A.J., Jampol L.M. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv. Ophthalmol. 2010;55(2):108–133. DOI: 10.1016/j.survophthal.2009.07.005Kim S.J., Schoenberger S.D., Thorne J.E Ehlers J., Yeh S., Bakri S. Topical nonsteroi dal anti-inflammatory drugs and cataract surgery: a report by the American Acad emy of Ophthalmology. Ophthalmology. 2015;122(11):2159–2168. DOI: 10.1016/j. ophtha.2015.05.014Kim S.J., Schoenberger S.D., Thorne J.E Ehlers J., Yeh S., Bakri S. Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(11):2159–2168. DOI: 10.1016/j. ophtha.2015.05.014Modjtahedi B.S., Paschal J.F., Batech M. Luong T, Fong D. Perioperative topical non steroidal anti-inflammatory drugs for macular edema prophylaxis following cata ract surgery. Am. J. Ophthalmol. 2017;176:174–182. DOI: 10.1016/j.ajo.2017.01.006Modjtahedi B.S., Paschal J.F., Batech M. Luong T, Fong D. Perioperative topical nonsteroidal anti-inflammatory drugs for macular edema prophylaxis following cataract surgery. Am. J. Ophthalmol. 2017;176:174–182. DOI: 10.1016/j.ajo.2017.01.006Sivaprasad S., Bunce C., Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br. J. Ophthalmol. 2005;89(11):1420–1422. DOI: 10.1136/bjo.2005.073817Sivaprasad S., Bunce C., Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br. J. Ophthalmol. 2005;89(11):1420–1422. DOI: 10.1136/bjo.2005.073817Celik T., Turkoglu E.B. Comparative evaluation of olopatadine 0.01 % combined fluorometholone 0.1 % treatment versus olopatadine 0.01 % combined ketorolac 0.4 % treatment in patients with acute seasonal allergic conjunctivitis. Curr. Eye Res. 2014;39(1):42–46. DOI: 10.3109/02713683.2013.827213Celik T., Turkoglu E.B. Comparative evaluation of olopatadine 0.01 % combined fluorometholone 0.1 % treatment versus olopatadine 0.01 % combined ketorolac 0.4 % treatment in patients with acute seasonal allergic conjunctivitis. Curr. Eye Res. 2014;39(1):42–46. DOI: 10.3109/02713683.2013.827213Donnenfeld E.D., Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09 %: the first twice-daily ophthalmic nonsteroidal antiinflammatory drug. Int. Ophthalmol. Clin. 2006;46(4):21–40. DOI: 10.1097/01. iio.0000212134.83513.11Donnenfeld E.D., Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09 %: the first twice-daily ophthalmic nonsteroidal antiinflammatory drug. Int. Ophthalmol. Clin. 2006;46(4):21–40. DOI: 10.1097/01. iio.0000212134.83513.11Waterbury L.D., Silliman D., Jolas T. Comparison of cyclooxygenase inhibi tory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr. Med. Res. Opin. 2006;22:1133–1140. DOI: 10.1185/030079906X112471Waterbury L.D., Silliman D., Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr. Med. Res. Opin. 2006;22:1133–1140. DOI: 10.1185/030079906X112471Yanni J.M., Graff G., Hellberg M.R. Topically administrable compositions containing 3- benzoylphenylaceteic acid derivatives for treatment of ophthalmic inflammatory disorders. Alcon Laboratories, Inc., assignee. US Patent 5,475,034. December 12, 1995.Yanni J.M., Graff G., Hellberg M.R. Topically administrable compositions containing 3benzoylphenylaceteic acid derivatives for treatment of ophthalmic inflammatory disorders. Alcon Laboratories, Inc., assignee. US Patent 5,475,034. December 12, 1995.Ogawa T., Miyake K., McNamara T.R. Pharmacokinetic profile of topically applied bromfenac sodium ophthalmic sodium ophthalmic solution 0.1 % in subjects undergo ing cataract surgery. Proceedings of the Association for Research in Vision and Oph thalmology (ARVO) Annual Meeting, Ft. Lauderdale, FL, April 30–May 4, 2006. A687.Ogawa T., Miyake K., McNamara T.R. Pharmacokinetic profile of topically applied bromfenac sodium ophthalmic sodium ophthalmic solution 0.1 % in subjects undergoing cataract surgery. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Ft. Lauderdale, FL, April 30–May 4, 2006. A687.Bakalyan G.A., Deshmukh H.M., Patterson H. Concentrations of radioactivity in ocular tissues after a single topical dose of C-bromfenac ophthalmic solution. Proceedings of the American Society of Cataract and Refractive Surgery (ASCRS) Meeting, San Francisco, CA, March 17–22, 2006. Abstract p. 227.Bakalyan G.A., Deshmukh H.M., Patterson H. Concentrations of radioactivity in ocular tissues after a single topical dose of C-bromfenac ophthalmic solution. Proceedings of the American Society of Cataract and Refractive Surgery (ASCRS) Meeting, San Francisco, CA, March 17–22, 2006. Abstract p. 227.Baklayan G.A., Muñoz M. The ocular distribution of 14C-labeled bromfenac oph thalmic solution 0.07 % in a rabbit model. Clin Ophthalmol. 2014;8:1717–1724. DOI: 10.2147/OPTH.S66638Baklayan G.A., Muñoz M. The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07 % in a rabbit model. Clin Ophthalmol. 2014;8:1717–1724. DOI: 10.2147/OPTH.S66638McNamara T.R., Baklayan G.A., Deshmukh H.M. Concentrations of radioactivity in ocular tissues after a single 0.09 % topical dose of C-bromfenac ophthalmic solu tion. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Ft. Lauderdale, FL, April 30–May 4, 2006. A687.McNamara T.R., Baklayan G.A., Deshmukh H.M. Concentrations of radioactivity in ocular tissues after a single 0.09 % topical dose of C-bromfenac ophthalmic solution. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Ft. Lauderdale, FL, April 30–May 4, 2006. A687.Kida T., Kozai S., Takahashi H., Isaka M., Tokushige H. Pharmacokinetics and Efficacy of Topically Applied Nonsteroidal Anti-Inflammatory Drugs in Retino choroidal Tissues in Rabbits. PLoS ONE 2014;9(5):e96481. DOI: 10.1371/journal. pone.0096481Kida T., Kozai S., Takahashi H., Isaka M., Tokushige H. Pharmacokinetics and Efficacy of Topically Applied Nonsteroidal Anti-Inflammatory Drugs in Retinochoroidal Tissues in Rabbits. PLoS ONE 2014;9(5):e96481. DOI: 10.1371/journal. pone.0096481Baklayan G.A., Patterson H.M., Song C.K. Gow J, McNamara T.R. 24-hour evalu ation of the ocular distribution of (14) C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J. Ocul. Pharmacol. Ther. 2008;24:392–398. DOI: 10.1089/jop.2007.0082Baklayan G.A., Patterson H.M., Song C.K. Gow J, McNamara T.R. 24-hour evaluation of the ocular distribution of (14) C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J. Ocul. Pharmacol. Ther. 2008;24:392–398. DOI: 10.1089/jop.2007.0082Donnenfeld E.D., Donnenfeld A. Global experience with Xibrom (bromfenac oph- thalmic solution) 0.09 %: the first twice-daily ophthalmic nonsteroidal an ti-inflam- matory drug, Int. Ophthalmol. Clin. 2006;46:21–40. DOI: 10.1097/01. iio.0000212134.83513.11Donnenfeld E.D., Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09 %: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug, Int. Ophthalmol. Clin. 2006;46:21–40. DOI: 10.1097/01. iio.0000212134.83513.11FitzGerald G.A., Patron C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. 2001;345:433–442. DOI: 10.1056/NEJM200108093450607FitzGerald G.A., Patron C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. 2001;345:433–442. DOI: 10.1056/NEJM200108093450607Gamache D.A., Graff G., Brady M.T. Yanni J.M. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflamma tion: I. Assesment of anti-inflammatory efficacy. Inflammation. 2000;24:357–370. DOI: 10.1023/a:1007049015148Gamache D.A., Graff G., Brady M.T. Yanni J.M. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assesment of anti-inflammatory efficacy. Inflammation. 2000;24:357–370. DOI: 10.1023/a:1007049015148Гобеджишвили М.В., Астахов С.Ю., Куглеев А.А. Макулярный отек при псевдофакии. Офтальмологические ведомости. 2011;4(4):57–59.Gobedzhishvili M.V., Astakhov S.Yu., Kugleev A.A. Macular edema in pseudophakia. Ophthalmology journal = Oftal’mologicheskie vedomosti. 2011;4(4):57–59 (In Russ.).Миронова Э.М. Прогнозирование развития постэкстракционной макуляр ной патологии. Офтальмохирургия. 1989;3:18–21.Mironova E.M. Predicting the development of post-extraction macular pathology. Ophthalmosurgery = Oftal’mohirurgiya. 1989;3:18–21 (In Russ.).Федоров С.Н., Егорова Э.В. Ошибки и осложнения при имплантации искусственного хрусталика. М.: Медицина. 1992. 244 с. [Fedorov S.N., Egorova E.V. Errors and complications in the implantation of an artificial lens. Moscow: Me dicina, 1992. 244 p. (In Russ.)].Fedorov S.N., Egorova E.V. Errors and complications in the implantation of an artificial lens. Moscow: Medicina, 1992. 244 p. (In Russ.).Gass J.D. Lamellar macular hole: a complication of cystoids macular edema after cataract extraction: a clinicopathologic case report. Trans. Am. Ophthalmol. Soc. 1975;73:230–250.Gass J.D. Lamellar macular hole: a complication of cystoids macular edema after cataract extraction: a clinicopathologic case report. Trans. Am. Ophthalmol. Soc. 1975;73:230–250.Goodman D.F., Stark W.J., Gottsch J.D. Complications of cataract extraction with intraocular lens implantation. Ophthalmic Surg. 1989;2(20):132–140.Goodman D.F., Stark W.J., Gottsch J.D. Complications of cataract extraction with intraocular lens implantation. Ophthalmic Surg. 1989;2(20):132–140.Bakunowicz-Lazarczyk A., Moniuszko T., Sredzinska-Kita D., Chwiecko J. Aque ous humor cytokines concentration in patients operated on cataract. Klin. Oczna. 1997;99:235–237.Bakunowicz-Lazarczyk A., Moniuszko T., Sredzinska-Kita D., Chwiecko J. Aqueous humor cytokines concentration in patients operated on cataract. Klin. Oczna. 1997;99:235–237.Behndig A., Lundberg B.J. Transient corneal edema after phacoemulsification: com parison of 3 viscoelastic regimens. J. Cataract Refract. Surg. 2002;28(9):1551–1556. DOI: 10.1016/s0886-3350(01)01219-6Behndig A., Lundberg B.J. Transient corneal edema after phacoemulsification: comparison of 3 viscoelastic regimens. J. Cataract Refract. Surg. 2002;28(9):1551–1556. DOI: 10.1016/s0886-3350(01)01219-6Behndig A., Lundberg B.J Mydriatic response to different concentrations of intra cameral phenylephrine in humans. J. Cataract Refract. Surg. 2010;36(10):1682– 1686. DOI: 10.1016/j.jcrs.2010.04.036Behndig A., Lundberg B.J Mydriatic response to different concentrations of intracameral phenylephrine in humans. J. Cataract Refract. Surg. 2010;36(10):1682– 1686. DOI: 10.1016/j.jcrs.2010.04.036Bergstrom S., Ryhage R., Samuelsson, Sjovall J. The structure of prostaglandin E F1 and F2. Acta Chem. Scand. 1962;16(2):501–502.Bergstrom S., Ryhage R., Samuelsson, Sjovall J. The structure of prostaglandin E F1 and F2. Acta Chem. Scand. 1962;16(2):501–502.Родин А.С. Новые клинические возможности метода оптической когерентной томографии. Ранняя диагностика патологии макулы у пациентов с высокой остротой зрения. Офтальмология. 2004;1(4):24–28.Rodin A.S. New clinical possibilities of the method of optical coherence tomography. Early diagnosis of macular pathology in patients with high visual acuity. Ophalmology in Russia = Oftal’mologiya. 2004;1(4):24–28 (In Russ.).Lebraud P., Adenis J.P., Franco J.L. Peigne G, Mathon C. Cystoid macular edema of pseudophakic patients (retrospective study with 300 pseudophakic patients). Bull. Soc. Ophthalmol. Fr. 1987;87(12):1437–1439.Lebraud P., Adenis J.P., Franco J.L. Peigne G, Mathon C. Cystoid macular edema of pseudophakic patients (retrospective study with 300 pseudophakic patients). Bull. Soc. Ophthalmol. Fr. 1987;87(12):1437–1439.Jaffe N.S. Thirty years of intraocular lens implantation: The way it was and the way it is. Journal of Cataract and Refractive Surgery. 1999;25(4):455–459. DOI: 10.1016/ s0886-3350(99)80028-5Jaffe N.S. Thirty years of intraocular lens implantation: The way it was and the way it is. Journal of Cataract and Refractive Surgery. 1999;25(4):455–459. DOI: 10.1016/ s0886-3350(99)80028-5Jaffe N.S. Vitreous traction at the posterior pole of the fundus due to alterations in the posterior vitreous. Trans. Amer. Acad. Ophthalmol. Otolaryng.1967;71(4):642–652.Jaffe N.S. Vitreous traction at the posterior pole of the fundus due to alterations in the posterior vitreous. Trans. Amer. Acad. Ophthalmol. Otolaryng.1967;71(4):642–652.Mentes J., Erakgun T., Afrashi F., Kerci G. Incidence of cystoids macular edema after uncomplicated phacoemulsification. Ophthalmologica. 2003;217(6):408–412. DOI: 10.1159/000073070Mentes J., Erakgun T., Afrashi F., Kerci G. Incidence of cystoids macular edema after uncomplicated phacoemulsification. Ophthalmologica. 2003;217(6):408–412. DOI: 10.1159/000073070Henderson B.A., Pineda R. Essentials of cataract surgery. Slack. Inc., 2007. P. 187–200.Henderson B.A., Pineda R. Essentials of cataract surgery. Slack. Inc., 2007. P. 187–200.Gross J.G. Xibrom (bromfenac) reduces cystoid macular edema associated with vein occlusions, macular epiretinal membrane, diabetic retinopathy and age related macular degeneration. Poster F-3 presented at: Annual Meeting of the Retina Soci ety. September 27–30; Boston.Gross J.G. Xibrom (bromfenac) reduces cystoid macular edema associated with vein occlusions, macular epiretinal membrane, diabetic retinopathy and age related macular degeneration. Poster F-3 presented at: Annual Meeting of the Retina Society. September 27–30; Boston.Gross J. Xibrom (bromfenac) reduces macular edema associated with vein occlu sion, macular epiretinal membrane, diabetic retinopathy and age related macular degeneration. Poster F-3, 40th Meeting of thr Retina Society, Boston, 2007.Gross J. Xibrom (bromfenac) reduces macular edema associated with vein occlusion, macular epiretinal membrane, diabetic retinopathy and age related macular degeneration. Poster F-3, 40th Meeting of thr Retina Society, Boston, 2007.Donnenfeld E.D., Holland E.J., Stewart R.H., Gow J., Grillone L. Bromfenac oph thalmic solution 0.09 % (Xibrom) for post-operative ocular pain and inflammation. Ophthalmology. 2007;114:1653–1662. DOI: 10.1016/j.ophtha.2006.12.029Donnenfeld E.D., Holland E.J., Stewart R.H., Gow J., Grillone L. Bromfenac ophthalmic solution 0.09 % (Xibrom) for post-operative ocular pain and inflammation. Ophthalmology. 2007;114:1653–1662. DOI: 10.1016/j.ophtha.2006.12.029Rho D.S., Soll S.M., Markovitz B.J. Bromfenac 0.09 % versus diclofenac sodium 0.1 % versus ketorolac tromethamine 0.5 % in the treatment of acute pseudophakic cystoid macular edema. Invest.Ophthalmol. Vis. Sci. 2006. 47 p.Rho D.S., Soll S.M., Markovitz B.J. Bromfenac 0.09 % versus diclofenac sodium 0.1 % versus ketorolac tromethamine 0.5 % in the treatment of acute pseudophakic cystoid macular edema. Invest.Ophthalmol. Vis. Sci. 2006. 47 p.Jones J., Francis P. Ophthalmic utility of topical bromfenac, a twicedaily nonsteroi dal anti-inflammatory agent. Expert. Opin. Pharmacother. 2009;10(14):2379–2385. DOI: 10.1517/14656560903188425Jones J., Francis P. Ophthalmic utility of topical bromfenac, a twicedaily nonsteroidal anti-inflammatory agent. Expert. Opin. Pharmacother. 2009;10(14):2379–2385. DOI: 10.1517/14656560903188425Silverstein S.M., Jackson M.A., Goldberg D.F., Muñoz M. The efficacy of bromfenac ophthalmic solution 0.07 % dosed once daily in achieving zeroto-trace anterior chamber cell severity following cataract surgery. Clin. Ophthalmol. 2014;8:965–972. DOI: 10.2147/OPTH.S60292Silverstein S.M., Jackson M.A., Goldberg D.F., Muñoz M. The efficacy of bromfenac ophthalmic solution 0.07 % dosed once daily in achieving zeroto-trace anterior chamber cell severity following cataract surgery. Clin. Ophthalmol. 2014;8:965–972. DOI: 10.2147/OPTH.S60292Almeida D.R., Johnson D., Hollands H., Smallman D., Baxter S., Eng K., Kratky V., Hove M., Sharma S., El-Defrawyet S. Effect of prophylactic nonsteroidal antiinflam matory drugs on cystoid macular edema assessed using optical coherence tomogra phy quantification of total macular volume after cataract surgery. J. Cataract Refract. Surg. 2008;34:64–69. DOI: 10.1016/j.jcrs.2007.08.034Almeida D.R., Johnson D., Hollands H., Smallman D., Baxter S., Eng K., Kratky V., Hove M., Sharma S., El-Defrawyet S. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J. Cataract Refract. Surg. 2008;34:64–69. DOI: 10.1016/j.jcrs.2007.08.034Kim S.J., Equi R., Bressler N.M. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114:881–889. DOI: 10.1016/j.ophtha.2006.08.053Kim S.J., Equi R., Bressler N.M. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114:881–889. DOI: 10.1016/j.ophtha.2006.08.053Kato S., Fukada Y., Hori S., Tanaka Y., Oshika T. Influence of phacoemulsification and intraocular lens implantation on the course of diabetic retinopathy. J. Cataract Refrac.t Surg. 1999;25:788–793.Kato S., Fukada Y., Hori S., Tanaka Y., Oshika T. Influence of phacoemulsification and intraocular lens implantation on the course of diabetic retinopathy. J. Cataract Refrac.t Surg. 1999;25:788–793.Song S.H. Effect of 0.1 % Bromfenac for Preventing Macular Edema after Cata ract Surgery in Patients with Diabetes. Korean Journal of Ophthalmology: KJO. 2020;34(1):46–55. DOI: 10.3341/kjo.2019.0044Song S.H. Effect of 0.1 % Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes. Korean Journal of Ophthalmology: KJO. 2020;34(1):46–55. DOI: 10.3341/kjo.2019.0044Donnenfeld E.D., Holland E.J., Stewart R. Topical Xibrom 0.1 % an investigational NSAID, significantlyand rapidly decreased post-cataract surgery inflammation and reduced ocular pain. Invest. Ophthalmol. Vis. Sci. 2005;46:E-abstract 791.Donnenfeld E.D., Holland E.J., Stewart R. Topical Xibrom 0.1 % an investigational NSAID, significantlyand rapidly decreased post-cataract surgery inflammation and reduced ocular pain. Invest. Ophthalmol. Vis. Sci. 2005;46:E-abstract 791.Cable M., Clinical outcomes of BROMDAY Versus Nepafenac, Presented at: Annual Meeting of American Siciety of Retinal Specialists, Boston, October 2011.Cable M., Clinical outcomes of BROMDAY Versus Nepafenac, Presented at: Annual Meeting of American Siciety of Retinal Specialists, Boston, October 2011.Томилова Е.В., Немсицверидзе М.Н., Панова И.Е. Влияние медикаментозной терапии на эпителизацию роговичного разреза после факоэмульсификации. Вестник офтальмологии. 2017;3:6–11. DOI: 10.17116/oftalma20171333Tomilova E.V., Nemsitsveridze M.N., Panova I.E. Effect of medicinal treatment on epithelial wound healing after phacoemulsification. Annals of Ophthalmology = Vestnik oftal’mologii 2017;3:6–11 (In Russ.). DOI: 10.17116/oftalma20171333Ohara K., Ohkubo A., Miyamoto T. Prevention of miosis during cataract surgery by topical bromfenac sodium. Rinsho Ganka (Jpn J Clin Ophthalmol). 2004;58:1325– 1328.Ohara K., Ohkubo A., Miyamoto T. Prevention of miosis during cataract surgery by topical bromfenac sodium. Rinsho Ganka (Jpn J Clin Ophthalmol). 2004;58:1325– 1328.Ocular NSAIDs: a new option. Insert. to Cataract & Refractive Surgery Today, March, 2006. P. 8.Ocular NSAIDs: a new option. Insert. to Cataract & Refractive Surgery Today, March, 2006. P. 8.Usui M., Masuda K. Effect of bromfenac sodium (AHR-10282B) eye drops on ante rior uveitis. J Rev Clin Ophthalmol. 1997;91:39–44.Usui M., Masuda K. Effect of bromfenac sodium (AHR-10282B) eye drops on anterior uveitis. J Rev Clin Ophthalmol. 1997;91:39–44.Ocular Surgery News: Ista announces positive results from phase 2 trial of low- dose bromfenac in dry eye disease, June 9, 2009.Ocular Surgery News: Ista announces positive results from phase 2 trial of lowdose bromfenac in dry eye disease, June 9, 2009.Schechter B.A. Ketorolac during the induction phase of cyclosporin-A therapy J. Ocular. Pharmacol. Ther., 2006 Apr;22(2):150–154. DOI: 10.1089/jop.2006.22.150Schechter B.A. Ketorolac during the induction phase of cyclosporin-A therapy J. Ocular. Pharmacol. Ther., 2006 Apr;22(2):150–154. DOI: 10.1089/jop.2006.22.150Miyake-Kashima M., Takano Y., Tanaka M., Satake Y., Kawakita T., Dogru M., Asa no-Kato N., Fukagawa K., Fujishima H. Comparision of 0.1 % bromfenac sodium and 0.1 % pemirolast potassium for the treatment of allergic conjunctivitis. Jpn. J. Ophthalmol. 2004;48:587–590. DOI: 10.1007/s10384-004-0127-2Miyake-Kashima M., Takano Y., Tanaka M., Satake Y., Kawakita T., Dogru M., Asano-Kato N., Fukagawa K., Fujishima H. Comparision of 0.1 % bromfenac sodium and 0.1 % pemirolast potassium for the treatment of allergic conjunctivitis. Jpn. J. Ophthalmol. 2004;48:587–590. DOI: 10.1007/s10384-004-0127-2Fujishima H., Fukagawa K., Takano Y., Tanaka M., Okamoto S., Miyazaki D., Ya mada J., Fukushima A., Uchio E., Nakagawa Y. Comparison of efficacy of bromf enac sodium 0.1 % ophthalmic solution and fluorometholone 0.02 % ophthalmic suspension for the treatment of allergic conjunctivitis, J. Ocul. Pharmacol. Ther. 2009;25(3):265–270. DOI: 10.1089/jop.2008.0121Fujishima H., Fukagawa K., Takano Y., Tanaka M., Okamoto S., Miyazaki D., Yamada J., Fukushima A., Uchio E., Nakagawa Y. Comparison of efficacy of bromfenac sodium 0.1 % ophthalmic solution and fluorometholone 0.02 % ophthalmic suspension for the treatment of allergic conjunctivitis, J. Ocul. Pharmacol. Ther. 2009;25(3):265–270. DOI: 10.1089/jop.2008.0121Grant C.A Combination therapy: lucentis (ranibizumab injection) and xibrom (bromfenac ophthalmic solution) 0.09 % in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(E-Abstract 563).Grant C.A Combination therapy: lucentis (ranibizumab injection) and xibrom (bromfenac ophthalmic solution) 0.09 % in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(E-Abstract 563).Gomi F., Sawa M., Tsujikawa M., Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-re lated macular degeneration. Retina. 2012;32(9):1804–1810. DOI: 10.1097/ IAE.0b013e31825be87fGomi F., Sawa M., Tsujikawa M., Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina. 2012;32(9):1804–1810. DOI: 10.1097/ IAE.0b013e31825be87f

The authors declare that there are no conflicts of interest present.